Ionis Pharmaceuticals, Inc.
IONS · Healthcare
$59.88
Caricamento grafico…
Notizie
Ultime notizie su questo titolo
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
Royalty Pharma announced that Novartis' Phase 3 HORIZON trial for pelacarsen failed to meet its primary endpoint of reducing cardiovascular events in patients with elevated Lp(a). Despite the setback, Royalty Pharma expects to recoup its total $500 million investment and earn a modest positive return due to its protective deal structure that prioritized stable Spinraza royalties. The company reiterates its 2030 Portfolio Receipts target of $4.7 billion or more.
IONS Secures FDA Nod for Rare Brain Disorder Drug Zanvastro
Ionis Pharmaceuticals announced FDA approval of Zanvastro (zilganersen), the first disease-modifying treatment for rare neurological condition Alexander disease (AxD) in both pediatric and adult patients. The approval was supported by Phase III results showing statistically significant stabilization in gait speed. Ionis also received a rare pediatric disease priority review voucher. However, commercial potential is limited due to the ultra-rare nature of the condition affecting approximately 1 in 1-3 million people worldwide.
Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound?
Indivior Pharmaceuticals beat Q2 2026 earnings estimates with adjusted EPS of $1.15 (vs. $0.97 consensus) and revenues of $343 million (vs. $308 million consensus), driven by strong Sublocade performance. The company raised its full-year 2026 guidance and improved profitability through cost management. Despite these positive results, shares have declined 5.3% since the earnings report, underperforming the S&P 500. The stock holds a Zacks Rank #2 (Buy) with upward estimate revisions.
Multiple System Atrophy Clinical Trial Pipeline Gains Momentum: 22+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
The multiple system atrophy (MSA) clinical trial pipeline is experiencing significant momentum with 22+ companies developing 24+ pipeline drugs. The pipeline is diversifying beyond traditional approaches to include oral small molecules, cell replacement therapies, gene therapies, and next-generation alpha-synuclein inhibitors. Recent developments include Alterity Therapeutics achieving FDA alignment on Phase III for ATH434, Teva receiving Fast Track designation for TEV-56286, and iRegene Therapeutics enrolling the first patient in a randomized controlled trial for NouvNeu004 in China.
Breakfast News: A Conversation With Ionis CEO
Ionis Pharmaceuticals CEO Brett Monia discusses the company's progress in 2026, highlighting FDA approval for Tryngolza and upcoming results for Pelacarsen in heart disease treatment. The company targets cash flow break-even in 2028 and projects $7 billion in peak revenue from late-stage programs. With 13 neurology drugs in clinical trials, Ionis aims to establish itself as a leader in antisense technology beyond first-mover competitors.